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Abstract 
Aim: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mel-
litus complicated by chronic liver injury.
Methods: Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic 
liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes 
(transaminases, etc.) were evaluated.
Results: HbA1c was reduced from 8.48 ± 1.43% to 7.87 ± 1.35% (P < 0.001). Among liver enzymes, alanine ami-
notransferase (ALT) levels improved from 75.1 ± 45.2 to 65.8 ± 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans 
peptidase from 155.2 ± 161.1 to 133.2 ± 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty 
liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. 
An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes.
Conclusion: It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mel-
litus complicated by chronic liver injury, including liver cirrhosis.
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Background
The number of patients with diabetes mellitus (DM) is 
increasing recently in Japan, was estimated at 9.5 million 
cases in 2012 in reports by Japanese Ministry of Health, 
Labor and Welfare. Among persons with probable DM, 
the rates of patients receiving medical treatment are 
65.9% for men and 64.3% for women, percentages that 
remain far too low. Dipeptidyl-peptidase 4 (DPP-4) 
inhibitors have recently been developed as a new viable 
option for the treatment of DM other than for type 1 
DM (T1DM), and the first DPP-4 inhibitor in Japan, sit-
agliptin, was released in 2009. Subsequently, a variety of 
DPP-4 inhibitors have been released, so that there were 
seven DPP-4 inhibitors available by 2013.
The incretin hormones glucagon-like peptide-1 (GLP-
1) and glucose-dependent insulinotropic polypeptide 
(GIP) are released from the gastrointestinal tract in 
response to a meal, which stimulates glucose-depend-
ent insulin production and secretion via specific recep-
tors expressed on the islet β cells (Drucker 2002). DPP-4 
inhibitors exhibit serum glucose-decreasing action by 
inhibiting the decomposition of incretin hormones and 
increasing of insulin secretion (Drucker and Nauck 2006; 
Ahren 2007; Holst et  al. 2009; Omar and Ahren 2014). 
DPP-4 inhibitors have no effect on weight gain and pose 
little risk of hypoglycemia following a single administra-
tion, which are benefits that have resulted in recently 
increasing numbers of prescriptions. In addition, DPP-4 
inhibitors inhibit glucagon secretion, increase islet cell 
proliferation, and decrease cell apoptosis in vitro (Farilla 
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et al. 2002; Li et al. 2003). Since the existence of GLP-1 
receptors has been confirmed in several organs other 
than pancreas, such as stomach, heart, kidney, liver, 
lung, central nervous system, muscle cells, fat cells, and 
vascular endothelial cells (Ahren 2004), extra-pancreatic 
effects of DPP-4 inhibitors are also expected.
Patients with type 2 diabetes mellitus (T2DM) patients 
often also present with chronic liver injury, and a pre-
vious study showed that approximately 80% of T2DM 
patients have a fatty liver (Browning et al. 2004). In par-
ticular, non-alcoholic fatty liver disease (NAFLD) is a fre-
quent complication of T2DM (Arase et al. 2009), and is 
the most common form of chronic liver injury in many 
countries around the world (Angulo 2002). In addition, 
DM has been suggested to enhance the development of 
hepatocellular carcinoma in patients with chronic hepa-
titis C (Kawamura et al. 2008; Veldt et al. 2008). As stated 
above, DM is closely related to chronic liver injury. On 
the other hand, since most oral hypoglycemic agents are 
metabolized in the liver and may induce liver damage, the 
treatment of T2DM patients with chronic liver injury is 
often difficult (Nauck et al. 2007).
Since the DPP-4 inhibitor sitagliptin is minimally 
metabolized in the liver and over 80% is excreted in an 
unaltered state in the urine (Drucker and Nauck 2006), 
it is expected that the pharmacokinetic of sitagliptin will 
have few negative effects even in patients with chronic 
liver injury. Although previous studies have shown the 
efficacy and safety of sitagliptin in a few patients with 
NAFLD or chronic hepatitis C (Iwasaki et al. 2011; Arase 
et  al. 2013; Arase et  al. 2011), the investigations remain 
insufficient.
In this study, we investigated the efficacy and safety of 




We investigated previous prescriptions written in Tokyo 
Teishin Hospital, and found 1,148 patients with DM 
other than T1DM who were administered sitagliptin 
(50  mg/day) between April 2010, and September 2013. 
Among them, the DM of 122 patients was complicated 
by liver injury at the start of sitagliptin administration. 
We regarded a patient to have liver injury based on the 
following clinical data: (1) elevation of serum aspartate 
aminotransferase (AST) and/or alanine aminotrans-
ferase (ALT) levels, or (2) the existence of primary liver 
disease associated with thrombocytopenia with plate-
let counts below 100,000/μL. The causes of liver injury 
were assessed comprehensively from past medical his-
tories, drinking habits (daily alcohol consumption above 
or below 20  g), clinical data such as viral markers of 
hepatitis, liver fibrosis markers, antinuclear antibod-
ies, and imaging views by abdominal ultrasonography 
and/or computed tomography (CT). NAFLD was diag-
nosed for patients with fatty liver alleged by CT and/or 
ultrasound, with daily alcohol consumption below 20  g, 
and with negative hepatitis B and C virus and autoanti-
bodies. Alcoholic liver disease (ALD) was diagnosed for 
patients with elevated liver enzymes, with daily alcohol 
consumption above 20  g, and with negative hepatitis B 
and C virus and autoantibodies. Chronic hepatitis C (C–
CH) was diagnosed for patients with positive hepatitis C 
virus markers; antibody for hepatitis C virus or positive 
hepatitis C virus’ RNA. Autoimmune hepatitis (AIH) was 
diagnosed for patient with positive anti-nuclear antibody, 
elevated immunoglobulin G (IgG), negative anti-mito-
chondrial antibody, and with chronic hepatitis character-
ized by interface hepatitis or infiltration of plasma cells 
confirmed by liver biopsy. Moreover, patients with liver 
cirrhosis were diagnosed based on findings of CT and/
or ultrasound, which showed rough liver surface, rough 
echoic levels in liver, dull liver edge, splenomegaly, and 
ascites, and blood tests, which showed thrombocytope-
nia, and reduced biosynthetic capacity such as albumin, 
prothrombin, total cholesterol, and cholinesterase.
Clinical and laboratory evaluation
We conducted retrospective investigation of the 122 
patients based on the clinical data in their medical 
records at the start of sitagliptin administration (pre-
treatment) and at the end of the study period (September 
2013) (post-treatment). All included patients received 
sitagliptin for a minimum of 3  months. If sitagliptin 
administration was ceased for some reason prior to Sep-
tember 2013, the data at the time of cessation were used 
as the post-treatment values. Serum levels of AST, ALT, 
gamma-glut amyl-trans peptidase(γGT) and hemoglobin 
A1c (HbA1c, NGSP value) were compared pre- and 
post-treatment.
In addition, we investigated the clinical data classified 
by the type of chronic liver injury: the NAFLD group and 
ALD group. We also investigated the clinical data for the 
LC group independently.
Statistical analysis
SPSS ver. 20 for Windows software was used to perform 
statistical analysis. Data are expressed as mean  ±  SD 
unless indicated otherwise. The paired t test was used 
to compare the pre-treatment and post-treatment clini-
cal data. A p value <0.05 was considered statistically 
significant.
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Results
Characteristics of enrolled patients
Table  1 shows the characteristics before follow-up of 
the 122 patients (93 men and 29 women: mean age, 
58.5 ± 13.9) with DM complicated by chronic liver injury. 
Nineteen patients were diagnosed with LC, 10 with ALD, 
6 with C–CH, 2 with NAFLD and one with AIH. Two 
patients with NAFLD were considered to develop non-
alcoholic steatohepatitis (NASH), which shows the bal-
looning of hepatocytes, proliferation of inflammatory 
cells, and hepatic fibrosis in histology. LC patients were 
graded by their Child-Pugh score (Cholongitas et  al. 
2005), which suggests liver functional reserves, with 12 
classified as Child-Pugh A, 5 as Child-Pugh B, and 2 as 
Child-Pugh C.
The causes of chronic liver injury in the remaining 103 
patients (non-LC group) were NAFLD in 62 patients, 
ALD in 17 patients, C–CH in 3 patients and autoimmune 
hepatitis (AIH) in 1 patient. As one patient with AIH 
was treated by prednisolone, her DM was possibly exac-
erbated by steroid therapy. The causes of chronic liver 
injury in 20 patients were unknown due to insufficient 
clinical data.
Pre follow-up, 67 patients were receiving no oral hypo-
glycemic drugs; 25 patients were receiving one drug 
(biguanide (BG) in 9 patients, sulfonylurea (SU) in 8 
patients, insulin in 7 patients, and thiazolidine (TZD) in 
one patient); 26 patients were receiving two drugs (SU 
and BG in 16 patients, insulin and BG in 3 patients, TZD 
and BG in 3 patients, insulin and SU in 2 patients, and 
SU and α-glucosidase inhibitor (α-GI) in 2 patients); 4 
patients were receiving three drugs (insulin, BG and α-GI 
in 1 patient, insulin, SU and α-GI in 1 patient, SU, BG 
and TZD in 1 patient, and SU, BG and α-GI in 1 patient).
Changes in clinical data
The duration of sitagliptin administration was 13.7 ± 10.1  
months on average. The average HbA1c levels decreased 
from 8.48  ±  1.43 to 7.87  ±  1.35% (P  <  0.001). Among 
liver enzymes, average AST levels underwent no signifi-
cant change (from 56.0 ± 25.8 IU/L to 56.9 ± 27.6 IU/L, 
P  =  0.718), while average ALT levels decreased (from 
75.1 ±  45.2 to 65.8 ±  35.8  IU/L, P =  0.012), and aver-
age γGT levels decreased (from 155.2  ±  161.1 to 
133.2 ± 127.4 IU/L, P = 0.044) (Figures 1, 2).
As shown in Table 2, a reduction in HbA1c without any 
deterioration in liver enzymes was observed for patients 
whose liver injury was classified as either NAFLD or 
ALD (non-LC), although the reduction in HbA1c in the 
ALD group was not statistically significant. An analysis of 
patients with LC also showed a reduction in HbA1c with-
out a deterioration in liver enzymes (Table 3).
Safety of sitagliptin
Three patients developed mild hypoglycemia (one patient 
in the NAFLD group receiving sulfonylurea, one patient 
in the ALD group receiving insulin, and 1 patient in the 
LC group receiving sulfonylurea), but no severe cases of 
hypoglycemia were seen in this study. Four patients died 
during the follow-up period; one was due to myelopro-
liferative disease (71 year-old male in the LC group), one 
was due to brain hemorrhage (77  year-old male in the 
LC group), one was due to pneumonia (88 year-old male 
in the NAFLD group), and one was due to rupture of a 
Table 1 Baseline characteristics
The data represent the mean ± SD.
AIH in 1 patient and unknown cause in 20 patients in addition to the data above.
HbA1c hemoglobin A1c, AST aspartate aminotransferase, ALT alanin aminotransferase.
Total Non LC LC
NAFLD ALD C–CH
n 122 62 17 3 19
Age (years) 58.5 ± 13.9 55.9 ± 15.4 60.1 ± 10.9 53.6 ± 14.8 66.4 ± 8.7
Sex (male/female) 93/29 48/14 16/1 0/3 13/6
Duration of diabetes (years) 9.2 ± 7.5 8.0 ± 5.6 9.0 ± 6.9 10.3 ± 9.5 9.0 ± 4.8
BMI (kg/m2) 26.9 ± 5.4 28.0 ± 5.3 26.8 ± 5.4 29.3 ± 15.8 23.9 ± 2.8
Platelet (×104/μL) 18.3 ± 6.5 20.3 ± 5.7 19.0 ± 4.6 20.5 ± 6.6 9.3 ± 4.0
HbA1c (%) 8.48 ± 1.43 8.57 ± 1.23 8.29 ± 1.77 9.76 ± 2.70 8.12 ± 1.29
AST (IU/L) 56.0 ± 25.8 52.7 ± 25.3 66.5 ± 28.3 71.0 ± 26.2 60.4 ± 30.9
ALT (IU/L) 75.1 ± 45.2 79.2 ± 45.4 88.0 ± 67.4 94.0 ± 10.8 49.5 ± 28.4
γGT (IU/L) 155.2 ± 161.1 112.0 ± 80.4 232.8 ± 144.7 92.3 ± 47.4 277.6 ± 310.4
Duration of sitagliptin dosing (months) 13.7 ± 10.1 15.2 ± 10.0 10.6 ± 9.1 7.3 ± 6.6 9.1 ± 9.6
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hepatocellular carcinoma (65  year-old male in the LC 
group). We cannot deny the relationship between rupture 
of a hepatocellular carcinoma and sitagliptin adminis-
tration, because recently it has been demonstrated that 
CXCR4/CXCL12 axis exerts a variety of functions at dif-
ferent steps of hepatocellular carcinoma progression, and 
CXCL12 may be inactivated by DPP-4 cleavage (Ismael 
et al. 2014). No other adverse events developed, and no 
patients stopped sitagliptin treatment due to adverse 
effects.
Discussion
We have described the efficacy and safety of sitag-
liptin as a treatment for patients with DM compli-
cated by chronic liver injury. The present study shows 
that the administration of sitagliptin for an average of 
13.7 months resulted in 0.61% decrease in the level of 
HbA1c, as well as decreased ALT and γGT levels in 122 
patients including 19 patients with LC. The ALT and 
γGT levels did not decrease significantly when ana-
lyzed with respect to the causes of chronic liver injury, 
but the data suggest at least that no deterioration of 
AST, ALT and γGT levels was caused by sitagliptin. 
In particular, this study can be considered valuable in 
demonstrating that sitagliptin decreased HbA1c lev-
els without causing any deterioration in liver enzymes 
even in patients with LC.
Recently, several studies have examined the relation-
ships between DPP-4 or incretin hormones and liver. 
DPP-4 plays a role in fibroblast activation in the liver by 
activating hepatic stellate cells (Piazza et  al. 1989; Levy 
et  al. 1999), while sitagliptin, a DPP-4 inhibitor, attenu-
ates hepatic fibrosis by suppressing activated hepatic stel-
late cells in rats (Kaji et al. 2014). The GLP-1 receptor is 
present on human hepatocytes and has been shown to 
play a direct role in decreasing hepatic steatosis in vitro 
by modulating components of the insulin signaling path-
way (Gupta et al. 2010). GLP-1 suppresses hepatic lipo-
genesis by activating the cAMP-activated protein kinase 
(AMPK) pathway (Shlomo et  al. 2011). Although the 
investigations in  vivo are still insufficient, the data sug-
gest that DPP-4 inhibitors and GLP-1 receptor agonists 
may improve hepatic steatosis and suppress the progres-
sion of hepatic fibrosis.
NAFLD is the leading cause of chronic liver injury in 
T2DM, as was seen in this study. NAFLD is considered 







































Figure 2 Changes in ALT and γGT in all patients.
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and is particularly associated with insulin resistance, 
obesity, hypertension, and abnormalities in glucose and 
lipid metabolism (Chitturi et  al. 2002). The histological 
changes seen in NAFLD range over a wide spectrum, 
extending from simple steatosis, which is generally non-
progressive, to NASH, liver cirrhosis and liver failure, 
and, sometimes, even hepatocellular carcinoma (Lud-
wig et  al. 1980). It is expected that DPP-4 inhibitors 
and GLP-1 receptor agonists will be especially effective 
in treating T2DM patients with NAFLD, because sev-
eral studies have shown that the serum concentration 
of DPP-4 is high in NAFLD patients where it is related 
to insulin resistance (Firneisz et  al. 2010), and that 
the expression of GLP-1 receptor is reduced in NASH 
patients (Ding et al. 2006). A previous study showed that 
the administration of sitagliptin (50 mg/day) for 16 weeks 
resulted in significant decreases in serum HbA1c, AST, 
ALT and γGT levels in 30 NAFLD patients with T2DM 
(Iwasaki et  al. 2011), a finding that suggests sitagliptin 
improves the effects of fatty liver. Although significant 
decreases in the serum levels of AST, ALT and γGT were 
not found for 62 NAFLD patients in our study, further 
investigations are necessary to assess the efficacy of sit-
agliptin in NAFLD patients. Although our study included 
NAFLD patients co-treated with thiazolidine, which has 
the efficacy of improving liver histology and fibrosis in 
NASH patients (Boettcher et al. 2012), the conclusion has 
not been changed even if these patients were excluded 
from the analysis because the number of these patients 
was only 3.
We also investigated the efficacy and safety of sitaglip-
tin also in ALD and LC patients. In particular, efficacy 
and safety of sitagliptin in LC patients have not been 
sufficiently investigated until now. LC can be defined 
as the end stage of chronic liver disease with progres-
sive fibrosis, and can be fatal due to the development of 
hepatocellular carcinoma or liver failure (Bataller and 
Brenner 2005). It is often difficult to treat patients with 
T2DM complicated by liver diseases using oral hypo-
glycemic agents, because most existing oral hypoglyce-
mic agents are metabolized in the liver, which may lead 
to an increase in hypoglycemic episodes or a deteriora-
tion of liver function. Since the DPP-4 inhibitor sitaglip-
tin is only minimally metabolized in liver with over 80% 
excreted intact in urine (Drucker and Nauck 2006), it is 
expected that sitagliptin will reduce serum glucose lev-
els without causing a deterioration in liver enzymes even 
in LC patients. This study investigated 19 patients with 
LC including those with severely impaired hepatic func-
tional reserves (5 patients classified as Child-Pugh B and 
2 patients as Child-Pugh C), with no apparent deteriora-
tion in liver enzymes. Although the number of patients 
is low, the result can be considered valuable. Since a pre-
vious study showed that sitagliptin attenuates hepatic 
fibrosis by suppressing activated hepatic stellate cells 
in vitro (Kaji et al. 2014), it is worthy investigating further 
whether sitagliptin suppresses the progression of hepatic 
fibrosis in LC patients.
Although we believe our findings to be valuable, the 
limitations of this study are as follows. First, this study is 
a retrospective, observational study, and the duration of 
sitagliptin administration was not the same in all cases. 
Second, the number of patients was insufficient (122 
patients), and, moreover, the causes of chronic liver injury 
in 20 patients were unknown due to the lack of sufficient 
clinical data. Third, we only assessed liver enzymes such 
as serum AST, ALT and γGT levels, and the assessments 
for true liver function, such as serum albumin, prothrom-
bin, cholinesterase and bilirubin, are insufficient. Fourth, 
the degree of hepatic fibrosis was not assessed using 
objective markers such as serum hyaluronic acid or type 
Table 2 Changes in clinical data of diabetes mellitus complicated by chronic liver injury (NAFLD and ALD)
NAFLD group (n = 62) ALD group (n = 17)
Pre-treatment Post-treatment P value Pre-treatment Post-treatment P value
HbA1c (%) 8.57 ± 1.23 7.99 ± 1.22 <0.001 HbA1c (%) 8.29 ± 1.77 7.79 ± 1.42 0.099
AST (IU/L) 52.7 ± 25.3 55.5 ± 29.4 0.491 AST (IU/L) 66.5 ± 28.3 63.1 ± 22.0 0.563
ALT (IU/L) 79.2 ± 45.4 74.7 ± 41.5 0.398 ALT (IU/L) 88.0 ± 67.4 63.0 ± 26.1 0.083
γGT (IU/L) 112.0 ± 80.4 115.4 ± 95.7 0.713 γGT (IU/L) 232.8 ± 144.7 163.8 ± 102.3 0.023
Table 3 Changes in clinical data of diabetes mellitus com-
plicated by liver cirrhosis
LC group (n = 19)
Pre-treatment Post-treatment P value
HbA1c (%) 8.12 ± 1.29 7.38 ± 1.24 0.006
AST (IU/L) 60.4 ± 30.9 64.5 ± 33.3 0.628
ALT (IU/L) 49.5 ± 28.4 44.5 ± 24.3 0.483
γGT (IU/L) 277.6 ± 310.4 212.7 ± 277.5 0.237
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IV collagen 7S domain, or other modalities such as Fibro-
scan. Further investigations are necessary to assess effi-
cacy and safety of sitagliptin for the treatment of patients 
with DM complicated by chronic liver injury.
Conclusion
It is suggested that sitagliptin can be administered effec-
tively and safely to patients with diabetes mellitus com-
plicated by chronic liver injury, including those with liver 
cirrhosis.
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